Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
BörsenkürzelBHC
Name des UnternehmensBausch Health Companies Inc
IPO-datumSep 20, 1994
CEOAppio (Thomas J)
Anzahl der mitarbeiter20700
WertpapierartOrdinary Share
GeschäftsjahresendeSep 20
Addresse2150 St. Elzear Blvd. West
StadtLAVAL
BörseNASDAQ OMX NASDAQ Basic NYSE
LandCanada
PostleitzahlH7L 4A8
Telefon18003611448
Websitehttps://www.bauschhealth.com/
BörsenkürzelBHC
IPO-datumSep 20, 1994
CEOAppio (Thomas J)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten